Weekly Analysts’ Ratings Updates for Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NASDAQ: NBIX) recently received a number of ratings updates from brokerages and research firms:

• 4/22/2026 – Neurocrine Biosciences had its price target raised by Leerink Partners from $160.00 to $170.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – Neurocrine Biosciences had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 4/15/2026 – Neurocrine Biosciences was upgraded by Zacks Research from “strong sell” to “hold”.
• 4/10/2026 – Neurocrine Biosciences had its price target raised by Morgan Stanley from $173.00 to $185.00. They now have an “equal weight” rating on the stock.
• 4/7/2026 – Neurocrine Biosciences had its price target raised by Citigroup Inc. from $204.00 to $242.00. They now have a “buy” rating on the stock.
• 4/7/2026 – Neurocrine Biosciences had its price target raised by Canaccord Genuity Group Inc. from $164.00 to $200.00. They now have a “buy” rating on the stock.
• 4/7/2026 – Neurocrine Biosciences had its price target raised by Wedbush from $151.00 to $166.00. They now have an “outperform” rating on the stock.
• 4/7/2026 – Neurocrine Biosciences had its price target raised by HC Wainwright from $192.00 to $215.00. They now have a “buy” rating on the stock.
• 4/6/2026 – Neurocrine Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $185.00 price target on the stock.
• 3/12/2026 – Neurocrine Biosciences had its price target raised by JPMorgan Chase & Co. from $176.00 to $177.00. They now have an “overweight” rating on the stock.
• 2/24/2026 – Neurocrine Biosciences is now covered by Wolfe Research. They set an “outperform” rating and a $160.00 price target on the stock.
• 2/23/2026 – Neurocrine Biosciences was upgraded by Wolfe Research to “strong-buy”.

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.